XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (14555)	9/15/2000 10:51:31 AM
From: manfredhasler	Read Replies (5) of 17367

George, My problem is that the placebo group has only 9.9% mortality. The delay in treatment with the study drug does not affect the placebo arm. The selection process let to a study group with a mortality rate of around 10%. Not 30% as expected. Even if we add the 57 patients excluded from the study (maybe even retrospectively and not based on proper selection criteria) the mortality rate was only 20% (of the total of 450 patients with fulminant meningococcal sepsis). I guess the study protocol was however based on this - false - assumption of 30% mortality rate. And the 30% are still valid according to the commentary in the LANCET ... Now, my reasoning is that if the study was done properly one should expect to see a mortality rate near 30% in the placebo group. Only then the lack of efficacy with Neuprex could be attributed to a delay in treatment. Again, from my calculations I conclude that the overall screened patient population did indeed have the proper patients available for the study. So, I just wonder whether a wrong selection of the patients did give a wrong study group. Hopefully the full article will give some more insight. Regards, Manfred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next